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Antiphospholipid antibodies (aPL) have been found in the blood of patients with systemic and
neurological disease. The rare reports of aPL in cerebral spinal ﬂuid (CSF) have been limited mostly to
IgG and IgM anticardiolipin (aCL). Our published ﬁnding of IgA aPE in the CSF of a young stroke
victim prompted us to establish “normal” CSF aPL values for a panel of aPL, which included aCL,
antiphosphatidylserine (aPS), antiphosphatidylethanolamine (aPE) and antiphosphatidylcholine (aPC).
CSF samples were tested by ELISA for IgG, IgM and IgA aPL. In addition, the CSF samples were
tested for activity in the presence and absence of phospholipid (PL) binding plasma-proteins. A total of
24 data points were obtained for each CSF sample. We tested 59 CSF samples obtained from 59 patients
who were undergoing evaluation for systemic or neurologic diseases. All CSF samples had normal
protein, glucose and cell counts. Ten of the 59 CSF samples (17%) had elevated aPL optical density
(OD) values an order of magnitude higher than the other 49 CSF samples for one or more aPL
speciﬁcity and/or isotype. One CSF sample had both PL-binding protein dependent and independent
IgG aPE activity. Another CSF sample showed both IgG aPE and aPC reactivity. The remaining eight
CSF samples showed single aPL ﬁndings; IgG aPE (5), IgG aPC (1), IgG aCL (1) and IgM aPC (1).
Seven of 10 patients with elevated CSF values were females. As expected, most “normal” aPL OD
values were substantially lower in CSF than those we have reported in blood samples from volunteer
blood donors.
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INTRODUCTION
Antiphospholipid antibodies (aPL) in blood are associated
with neurological disorders and deﬁcits. These include
focal central nervous system thrombo-occlusive events
(Levine et al., 2002), chorea (Paus et al., 2001), migraine
headaches (Silvestrini et al., 1993), amnesia (Montalban
et al., 1989), visual abnormalities (Briley et al., 1989), as
well an psychosis (Chengappa et al., 1991; Schwartz
et al., 1998) and cognitive dysfunction (Denberg
et al., 1997; Jacobson et al., 1999). The associations of
aPL with neurologic conditions other than thrombo-
occlusive events have been considered “weak” and
attributable to an “epiphenomenon” rather than to
pathophysiologic mechanisms (Brey, 2000). A stronger
association between aPL and neurological disorders might
be easier to establish if aPL are sought and detected in the
cerebral spinal ﬂuid (CSF) of patients experiencing
neurologic symptoms. Historically, scarce reports of aPL
in CSF are limited mostly to IgG and IgM anticardiolipin
(aCL) detection (Marchiorri, 1990; Lolli et al., 1991;
Wang et al., 1992; Gallo et al., 1994; Yeh et al., 1994;
Martinez-Cordero, 1997; Jedryka-Goral et al., 2000; Lai
and Lan, 2000; Baraczka et al., 2002). Rarely are IgA aCL
sought (Wang et al., 1992). To our knowledge only one
report included testing for IgG and IgM antiphos-
phatidylserine (aPS) and antiphosphatidylethanolamine
(aPE) in CSF; the results were negative (Gallo
et al., 1994). Our ﬁnding of IgA aPE in the CSF of a
young stroke victim (Sokol et al., 2000), together with our
intent to continue testing additional CSF samples,
prompted us to undertake and establish “normal” aPL
values for CSF. Our ﬁndings form the basis of this report.
PATIENTS AND METHODS
Because of the potential risks associated with spinal taps
to healthy individuals we were unable to obtain CSF
samples from random donors. We opted to perform a
retrospective analysis using residual CSF that was
collected for diagnostic purposes and destined for
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include, however, CSF samples from two normal elderly
women who were tapped as volunteer participants in a
non-related study involving Alzheimer’s disease. This
study was approved by the Institutional Review Board at
Indiana University School of Medicine. Fifty-nine of 160
available CSF samples that met the following criteria were
selected: normal protein (15–45mg/dl), glucose
(40–70mg/dl) and cell counts (,10/cm
3) with a
minimum volume of 2.0ml after diagnostic testing was
complete. The CSF samples were stored at 48C until
selected for evaluation whereupon the CSF were stored at
2808C until tested for aPL. Because this was a
retrospective study and since the CSF samples were not
released for 7 days, awaiting the possible need for further
diagnostic testing, we were not able to collect blood
samples for aPL testing and CSF comparisons.
The patient/CSF-donor diagnoses were obtained by chart
review and are listed in Table I. The mean age was 34
years (range 1–73); 26 were males and 33 females.
Our in-house serum aPL ELISA tests for IgG, IgM and
IgA aPE, aPS, aCL and antiphosphatidylcholine (aPC) in
the presence (dependent) and absence (independent) of
supplemental PL-binding plasma proteins (McIntyre
et al., 2003a). A total of 24 tests were performed for
each CSF sample. The ELISA was modiﬁed for CSF
testing as previously published (Sokol et al., 2000).
Brieﬂy, the modiﬁcations included: (1) Dilution of CSF,
1:4; (2) each dilution was tested in duplicate and (3) to
ensure detection the ELISA plate wells containing CSF
were developed for 2h in the presence of substrate. Due to
decreased immunoglobulin levels in CSF we used a lesser
dilution than for serum aPL testing. Preliminary testing of
CSF at a 1:2 dilution found that some CSF samples clotted
or became gelatinous after dilution in the aPL buffers, this
did not occur in dilutions of 1:4. Testing was performed in
duplicate rather than in triplicate as in our serum aPL to
reduce the amount of CSF required to perform the 24 aPL
tests. CSF which had poor reproducibility was repeat
tested as were all CSF with elevated aPL values.
RESULTS
Compared to serum samples that are tested at dilutions of
1:100, the OD410 values obtained with CSF, diluted at 1:4,
were lower than those reported for 775 normal blood
donors (mean 0.013 vs. 0.028, respectively). Using the
ELISA modiﬁcations described above, the OD410 values
for CSF ranged from 0.000–0.375. The graphs depicting
the ELISA values inclusive of all 59 CSF samples are
shown in Fig. 1. The aPL data generated are non-
parametric, thus analyses by means plus or minus the
standard deviations are not statistically appropriate.
The small volume of CSF obtained left insufﬁcient
volume to measure total immunoglobulin G, M and A
levels after aPL testing. Thus, we were unable to index our
aPL isotype ﬁndings to published immunoglobulin levels
for CSF. Despite the overall low mean aPL CSF value of
0.013, there were 10/59 CSF patient samples that had one
or more OD410 aPL ELISA values more than an order of
magnitude above the others (.0.150, range: 0.150–
0.375). These 10 patients’ ELISA results and their ﬁnal
diagnoses are shown in Table II. The highest OD410 value,
0.375 was observed for PL-binding protein independent
IgG aPE and was found in the CSF obtained from an MS
patient. This patient also had elevated levels of PL-binding
protein dependent IgG aPE. Both IgG aPE and aPC were
found in the CSF of one patient with acute myelogenous
leukemia (AML). The remaining 8 positive CSF samples
were positive in but one of the 24 individual aPL tests
performed. Females comprised 56% of the CSF donors,
however, 70% of the CSF with elevated aPL were obtained
from female donors. While not signiﬁcant (P ¼ 0.2660, x
2
analysis), this demonstrates a trend which suggests that, as
in the blood, autoantibodies detected in CSF may be more
prevalent in females than in males. The CSF samples
obtained from the two elderly female controls showed
means of 0.011 and 0.003, respectively.
Drugs have been implicated in the appearance of the
lupus anticoagulant as well as other aPL. Because of
the reports linkingdrugs and aPL,we compiled a list of the
drugs used among the 59 participants in this study.
Including the over the counter (OTC) by prescription only,
there were 135 different drugs tallied. Making an
assumption that drugs found in the aPL negative group
of 49 patients were neither associated with nor responsible
for the appearance of aPL, we subtracted these drugs from
the drug list compiled for the 10 aPL positive patients.
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D.K. SOKOL et al. 8We realize, however, that this assumption may be
overreaching insofar as responses to antigenic stimuli
are based upon an individual’s genetic predisposition.
Nevertheless, seven drugs were listed for ﬁve of the 10
aPL positive patients that were not listed among the 49
aPL negative patients. These seven are found in Table III
along with the results of a literature search that sought
possible associations with aPL. The published studies
regarding valproate, risperidone and lamotrigine were
anecdotal, conﬂicting and limited to serum or plasma aCL
and/or lupus anticoagulant ﬁndings; none had examined
CSF. Thus, there does not appear to be any reproducible
FIGURE 1 aPL ﬁndings in 59 CSF samples. Each CSF was diluted separately into dilution buffers with and without supplemental phospholipid (PL)
binding plasma proteins (dependent and independent, respectively) prior to addition to PL coated ELISA wells. The distribution of ELISA readings
(OD410) for antiphosphatidylethanolamine (aPE), antiphosphatidylcholine (aPC), antiphosphatidylserine (aPS) and anticardiolipin (aCL) are shown.
OD410 ﬁndings for IgG (A), IgA (B) and IgM (C) are depicted in separate graphs.
aPL IN CSFaPL IN CSF 9association with these particular drugs and aPL induction.
The association shown for cyclosporine was limited to
bone marrow transplant recipients and their development
of lupus anticoagulants. There are many other cyclospo-
rine aPL associations in the literature, but these were
indirect as the patients taking this drug were aPL positive
prior to exposure.
DISCUSSION
The presence of aPL in CSF may help to explain certain
reported associations of aPL with many neurological
disorders and deﬁcits. Indeed, there is evidence that some
aPL detected in the central nervous system (CNS) may be
synthesized in situ and not result from extravasation
through the CNS-associated vasculature (Martinez-
Cordero, 1997; Sokol et al., 2000; Baraczka et al., 2002).
Although there are no published reports to conﬁrm that
intrathecally-produced aPL, do not escape into the
systemic circulation and vice versa, locally produced
aPL in the CNS might be responsible for some aPL-
associated symptoms in otherwise aPL seronegative
patients (Miret et al., 1997). To answer this question,
paired samples of blood and CSF are needed, but this was
not the objective of our present study. We undertook to
establish “normal” positive/negative cutoff values for CSF
aPL for future studies wherein paired blood/CSF samples
will be collected for comparisons. Nonetheless, to our
knowledge this is the ﬁrst in-depth recording of aPL in
CSF to appear. In addition to the four aPL speciﬁcities
tested with three different conjugated isotype probes (IgG,
IgM, IgA), we determined the PL-binding plasma protein
requirement for each PL-isotype combination.
In general, elevations of aPL in our “normal” CSF
samples were observed in patients with conditions
previously associated with aPL, for example, infarctions
(Levine et al., 2002), MS and demyelinating diseases
(Baraczka et al., 2002), and HIV (Leder et al., 2001).
The association of aPL with structural brain lesions such
as a tumor is not altogether surprising, as this has been
reported in rare cases (Liu et al., 1999). While few studies
to date have looked for an association between leukemia
and aPL (Stasi et al., 1993; Bulvik et al., 1995; Yahata
et al., 1997; Al-Abdulla et al., 2001; McIntyre and
Wagenknecht, 2001; Mitchell, 2003), there has been a
report of a pro-coagulant state with presence of aPL in
leukemic patients’ serum peri- and post-bone marrow
transplant (BMT) (Tsakiris et al., 1991). Both of the
patients diagnosed with leukemia in the latter study were
being considered for BMT at the time of lumbar puncture.
The importance of aPL detection in the presence and
absence of PL-binding plasma proteins is gaining
acceptance. Recently, there have been several papers
documenting the pathogenic effects of plasma protein
independent aPS on pregnancy associated tissues. Direct
binding of monoclonal aPS to human trophoblast,
inhibition of hCG production and blocking trophoblast
invasiveness have been observed for plasma protein
independent aPS (Katsuragawa et al., 1997; Di Simone
et al., 2000). The aPE we observed in the CSF of a
15-year-old stroke patient was plasma protein independent
(Sokol et al., 2000), and we have shown that certain aPL
associated with early rejection of solid organ grafts were
independent of plasma proteins (McIntyre and Wagen-
knecht, 2003). Indeed, the majority of CSF aPL described
in this report 10/12 were classiﬁed as plasma protein
independent. Had we not screened the samples indepen-
dent of supplemental plasma proteins, these 10 aPL
speciﬁcities would have gone missing. Although we
cannot attribute pathology to these CSF samples, the
possibility remains intriguing, especially knowing that the
tissues comprising the CNS are rich sources of potential
PL-binding protein independent aPL targets.
TABLE III Drugs unique to 5 aPL-positive patients
Drug name (generic) aPL association Reference(s)
Percocet (oxycodone/acetaminophen) No None
Fosamax (alendronate sodium)* No None
Depakene (valproic acid)* Yes/No Furmaga et al., 1997; Echaniz-Laguna et al., 1999
Risperdal (risperidone)* Yes/No Sarzi-Puttini et al., 2000; Kamijo et al., 2003
Lamictal (lamotrigine) Yes/No Furmaga et al., 1997; Echaniz-Laguna et al., 1999
Morphine Sulfate No None
Neoral (cyclosporine) Yes Greeno et al., 1995
*The same patient for these 3 drugs.
TABLE II aPL ELISA ﬁndings in “normal” CSF diluted in PL-binding
protein dependent (10%adult bovine plasma)and independent(1% BSA)
















IgG aPE Dependent MS* 0.273
IgG aPC Independent Lymphoma 0.153
AML* 0.166
IgG aCL Independent HIV 0.225
IgM aPC Dependent Brain tumor 0.180
*Single patients with two positive aPL.
D.K. SOKOL et al. 10Drug-induced aPL associations have been the subject of
severalpublications (reviewed in Haag and Spigset, 2002).
There are conﬂicting data regarding drug-associated aPL
and pathology with some authors concluding that drug-
induced aPL are not associated with thrombosis (Pardo
et al., 2001) while others report the frequency of
complications are the same as what is seen with the
autoimmune patients (Triplett et al., 1988). Considering
that the drugs listed in Table III were unique to the
putative aPL positive CSF samples, there were conﬂicting
data presented for valproic acid, risperidone and
lamotrigine. While some investigators directly implicated
the ﬁnding of lupus anticoagulant and aCL to these drugs
(Furmaga et al., 1997; Echaniz-Laguna et al., 1999),
others found no association (Sarzi-Puttini et al., 2000;
Kamijo et al., 2003). Lupus inhibitors did appear in bone
marrow transplant recipients subsequent to cyclosporine
exposure, but these patients were also exposed to many
other immunosuppressive drugs and therapies (Greeno
et al., 1995).
There are several caveats to relate regarding these
drug-associated aPL studies that might account for the
discrepancies. First, the methodology used for aPL
detection varied among the reporting laboratories. Some
investigators limited their aPL analyses to IgG only
whereas others reported IgG and IgM. Second, the
choices of buffers and proteins included in the buffer
diluents were different. Third, there has been and
remains an historical problem with standardization of
the ELISA used for aPL detection. Many of the
problems that confound aPL testing and reporting have
been presented and discussed in a recent review
(McIntyre et al., 2003b).
In summary, we have provided a basis for comparisons
of aPL activity in CSF. Nonetheless, we recommend that
patient history be carefully scrutinized for conditions
and/or occurrences with known aPL associations before
proceeding with studies of CSF aPL. Serum and CSF
comparisons, and when possible, CNS tissue samples
would be important to further understand the association
between aPL and neurologic disease.
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